BR9914878A - Composições farmacêuticas contendo inibidores da poli (adp-ribose) glicohidrolase e métodos de sua utilização - Google Patents
Composições farmacêuticas contendo inibidores da poli (adp-ribose) glicohidrolase e métodos de sua utilizaçãoInfo
- Publication number
- BR9914878A BR9914878A BR9914878-1A BR9914878A BR9914878A BR 9914878 A BR9914878 A BR 9914878A BR 9914878 A BR9914878 A BR 9914878A BR 9914878 A BR9914878 A BR 9914878A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- ribose
- adp
- pharmaceutical compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Abstract
"COMPOSIçõES FARMACêUTICAS CONTENDO INIBIDORES DA POLI (ADP-RIBOSE) GLICOHIDROLASE E MéTODOS DE SUA UTILIZAçãO". A presente invenção está relacionada com composições farmacêuticas que contêm inibidores da poli (ADP-ribose)glicohidrolase, também conhecidos como inibidores PARG, e métodos de sua utilização para inibir ou reduzir a depleção da energia celular induzida por radicais livres, dano ou morte celular. Mais particularmente, a presente invenção também está relacionada a composições farmacêuticas que contêm inibidores de poli ADP- ribose glicohidrolase tais como derivados da glicose: lignina glicosídios; taninas hidrolisáveis incluindo galotanina e elagitanina; derivados da adenosídios; derivados de acridina incluindo 6,9-diamino-2-etoxiacridina lactato monohidratado; análogos da tilorona incluindo tilorona R10 556, daunomicina ou hidrocloreto de daunorubicina; elipticina; proflavina e outros inibidores PARG e seus métodos de utilização no tratamento e prevenção de doenças ou condições relativas a radicais livres que induzem depleção da energia celular e/ou dano tecidual resultante de dano ou morte celular em virtude de necrose, apoptose ou suas combinações.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/182,645 US20030078212A1 (en) | 1998-10-30 | 1998-10-30 | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
PCT/US1999/025521 WO2000025787A1 (en) | 1998-10-30 | 1999-11-01 | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9914878A true BR9914878A (pt) | 2003-01-07 |
Family
ID=22669416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9914878-1A BR9914878A (pt) | 1998-10-30 | 1999-11-01 | Composições farmacêuticas contendo inibidores da poli (adp-ribose) glicohidrolase e métodos de sua utilização |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030078212A1 (pt) |
EP (1) | EP1171130A4 (pt) |
JP (1) | JP2002540060A (pt) |
KR (1) | KR20010113632A (pt) |
CN (1) | CN1367693A (pt) |
AU (1) | AU777503B2 (pt) |
BR (1) | BR9914878A (pt) |
CA (1) | CA2350052A1 (pt) |
CZ (1) | CZ20011389A3 (pt) |
HK (1) | HK1041595A1 (pt) |
HU (1) | HUP0300886A2 (pt) |
IL (1) | IL142770A0 (pt) |
MX (1) | MXPA01004340A (pt) |
NO (1) | NO20011950L (pt) |
PL (1) | PL356063A1 (pt) |
WO (1) | WO2000025787A1 (pt) |
ZA (1) | ZA200103566B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585716B2 (en) * | 2000-04-05 | 2003-07-01 | Biocardia, Inc. | Method of treating the heart |
US6866875B2 (en) | 2001-09-26 | 2005-03-15 | Tampa Bay Research Institute | Pine cone extracts and uses thereof |
US7838046B2 (en) * | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Plant extracts and uses thereof |
WO2004009094A1 (en) * | 2002-07-24 | 2004-01-29 | Ohio University | Methods and compositions for treating diabetes mellitis |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US7176188B2 (en) * | 2003-05-07 | 2007-02-13 | UniversitéLaval | Method of lethally sensitizing human and animal cells |
WO2004111270A2 (en) * | 2003-06-13 | 2004-12-23 | The Babraham Institute | Differential gene expression in schizophrenia |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
EP2236131A3 (en) * | 2003-07-01 | 2011-03-02 | President and Fellows of Harvard College | Sirt1 modulators for manipulating cell/organism lifespan/stress response |
EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
WO2006007411A2 (en) * | 2004-06-16 | 2006-01-19 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-mediated apoptosis |
US20060014705A1 (en) * | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
CA2627319A1 (en) * | 2005-11-30 | 2007-06-07 | Prakash Jagtap | Purine derivatives and methods of use thereof |
JP2007223974A (ja) * | 2006-02-24 | 2007-09-06 | Japan Health Science Foundation | ポリ(adp−リボース)グリコヒドロラーゼ分解耐性のポリ(エテノadp−リボース) |
US8734867B2 (en) * | 2007-12-28 | 2014-05-27 | Liveleaf, Inc. | Antibacterial having an extract of pomegranate combined with hydrogen peroxide |
JP2012519690A (ja) | 2009-03-04 | 2012-08-30 | メタアクティブ、インコーポレイテッド | 生体分子の部位活性化複合体形成方法及び材料 |
WO2011085454A1 (en) * | 2010-01-18 | 2011-07-21 | Katholieke Universiteit Leuven K.U.Leuven R&D | Gp120 -binding benzene compounds and saccharide compounds |
MX354875B (es) | 2010-12-23 | 2018-03-22 | Amazentis Sa | Composiciones y métodos para mejorar la función mitocondrial y tratar enfermedades neurodegenerativas y trastornos cognitivos. |
US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
US8722040B2 (en) | 2011-06-24 | 2014-05-13 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
US8716351B1 (en) | 2012-12-23 | 2014-05-06 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms |
JP2017511382A (ja) * | 2014-04-04 | 2017-04-20 | ユニヴァーシティ オブ ロード アイランド リサーチ ファウンデーション | ガロタンニンを使用する皮膚美白方法 |
WO2015178791A1 (ru) * | 2014-05-23 | 2015-11-26 | Артур Викторович МАРТЫНОВ | Косметологическая и фармацевтическая композиция |
RU2564731C1 (ru) * | 2014-05-26 | 2015-10-10 | Общество с ограниченной ответственностью "Уникат" | Устройство нагрева локальных участков трубопровода |
JP2020510678A (ja) | 2017-03-08 | 2020-04-09 | アマゼンティス エスアーAmazentis Sa | 対象におけるマイトファジーを改善するための方法 |
CN109125337B (zh) * | 2018-07-23 | 2021-06-22 | 澳门科技大学 | 赶黄草化合物在制备治疗动脉粥样硬化的药物中的应用 |
CN110448563A (zh) * | 2019-07-19 | 2019-11-15 | 南京中医药大学 | 1,2,3,4,6-五没食子酰葡萄糖在制备防治骨质疏松症药品中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0103878B1 (de) * | 1982-09-17 | 1990-12-27 | Humán Oltoanyagtermelö és Kutato Intézet | Präparate zur Behandlung von Wunden der Hautoberfläche und Verfahren zur Herstellung derartiger Präparate |
JPH0759515B2 (ja) * | 1986-10-21 | 1995-06-28 | 株式会社ツムラ | アルド−スリダクタ−ゼ阻害剤 |
JP2784605B2 (ja) * | 1990-04-28 | 1998-08-06 | 靖一 田沼 | リグニン配糖体およびその用途 |
JP3067233B2 (ja) * | 1991-03-04 | 2000-07-17 | ウェルファイド株式会社 | アデノシン誘導体およびその用途 |
JP3185802B2 (ja) * | 1991-03-04 | 2001-07-11 | ウェルファイド株式会社 | ポリ(adp−リボース)グリコヒドロラーゼ阻害剤 |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
DE4415087A1 (de) * | 1994-04-29 | 1995-11-09 | Zschiegner Hans Joachim Dr | Mittel als Wirkstoffe bzw. Wirkstoffgemische zur Anwendung in der Balneotherapie, Gesundheitspflege und Kosmetik und Verfahren zur Herstellung pharmazeutischer Erzeugnisse sowie Verfahren zu ihrer Anwendung |
US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
WO1999011644A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
-
1998
- 1998-10-30 US US09/182,645 patent/US20030078212A1/en not_active Abandoned
-
1999
- 1999-11-01 KR KR1020017005357A patent/KR20010113632A/ko not_active Application Discontinuation
- 1999-11-01 CZ CZ20011389A patent/CZ20011389A3/cs unknown
- 1999-11-01 IL IL14277099A patent/IL142770A0/xx unknown
- 1999-11-01 JP JP2000579228A patent/JP2002540060A/ja active Pending
- 1999-11-01 MX MXPA01004340A patent/MXPA01004340A/es unknown
- 1999-11-01 CN CN99816808A patent/CN1367693A/zh active Pending
- 1999-11-01 WO PCT/US1999/025521 patent/WO2000025787A1/en not_active Application Discontinuation
- 1999-11-01 AU AU13325/00A patent/AU777503B2/en not_active Ceased
- 1999-11-01 PL PL99356063A patent/PL356063A1/xx not_active Application Discontinuation
- 1999-11-01 EP EP99956794A patent/EP1171130A4/en not_active Withdrawn
- 1999-11-01 HU HU0300886A patent/HUP0300886A2/hu unknown
- 1999-11-01 BR BR9914878-1A patent/BR9914878A/pt not_active IP Right Cessation
- 1999-11-01 CA CA002350052A patent/CA2350052A1/en not_active Abandoned
-
2001
- 2001-04-19 NO NO20011950A patent/NO20011950L/no not_active Application Discontinuation
- 2001-05-03 ZA ZA200103566A patent/ZA200103566B/en unknown
-
2002
- 2002-04-27 HK HK02103160.6A patent/HK1041595A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1041595A1 (zh) | 2002-07-12 |
NO20011950D0 (no) | 2001-04-19 |
JP2002540060A (ja) | 2002-11-26 |
WO2000025787A1 (en) | 2000-05-11 |
PL356063A1 (en) | 2004-06-14 |
IL142770A0 (en) | 2002-03-10 |
US20030078212A1 (en) | 2003-04-24 |
MXPA01004340A (es) | 2003-06-06 |
KR20010113632A (ko) | 2001-12-28 |
HUP0300886A2 (hu) | 2003-07-28 |
CZ20011389A3 (cs) | 2001-09-12 |
ZA200103566B (en) | 2002-12-03 |
AU1332500A (en) | 2000-05-22 |
CN1367693A (zh) | 2002-09-04 |
NO20011950L (no) | 2001-06-25 |
EP1171130A1 (en) | 2002-01-16 |
EP1171130A4 (en) | 2004-05-19 |
AU777503B2 (en) | 2004-10-21 |
CA2350052A1 (en) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9914878A (pt) | Composições farmacêuticas contendo inibidores da poli (adp-ribose) glicohidrolase e métodos de sua utilização | |
Chataing et al. | Inhibition of Trypanosoma cruzi growth in vitro by Solanum alkaloids: a comparison with ketoconazole | |
BR0008614A (pt) | Compostos inibidores tricìclicos de poli(adp-ribose) polimerases, seus sais, pró-medicamentos, metabólitos ativos, ou solvatos farmaceuticamente aceitáveis, composições farmacêuticas, métodos de inibição da atividade de parp de uma enzima e métodos de inibição da atividade de enzima parp em tecido de mamìfero | |
BR0213522B8 (pt) | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | |
BR9810097A (pt) | Derivados de macrolìdeos c-4-substituìdos | |
BR0015911A (pt) | Derivados de benzoimidazole úteis como agentes antiproliferativos | |
BR0116216A (pt) | Inibidores de girase e seus usos | |
BR9906013A (pt) | Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos | |
BRPI0313942B8 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
NO952132L (no) | Farmakologiske aktive pyridin-derivater og deres fremstilling | |
BRPI9913138B8 (pt) | derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo | |
BR0111548A (pt) | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal | |
BR9900856A (pt) | Antibioticos macrolideos de 3,6-cetal e enol-éter | |
BRPI0108394B8 (pt) | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos | |
NZ504986A (en) | Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents | |
GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
BRPI9810519A (pt) | derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. | |
BRPI0412899A (pt) | composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos | |
BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
MY103365A (en) | 4-demethoxy-4-amino-anthracyclines | |
ME00467B (me) | 13-točlani azalidi i njihova primena kao antibiotičkih sredstava | |
HUP0103112A2 (hu) | Glikogén foszforiláz inhibitorok alkalmazása daganatnövekedés gátlására | |
BR9813317A (pt) | Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto | |
ATE260109T1 (de) | Darmentzündungen vorbeugendes und therapeutisches arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007. |